FI970115A0 - Komposition innehållande nukleinsyror, dess framställning och användningar - Google Patents

Komposition innehållande nukleinsyror, dess framställning och användningar

Info

Publication number
FI970115A0
FI970115A0 FI970115A FI970115A FI970115A0 FI 970115 A0 FI970115 A0 FI 970115A0 FI 970115 A FI970115 A FI 970115A FI 970115 A FI970115 A FI 970115A FI 970115 A0 FI970115 A0 FI 970115A0
Authority
FI
Finland
Prior art keywords
preparation
nucleic acids
pct
containing nucleic
date feb
Prior art date
Application number
FI970115A
Other languages
English (en)
Finnish (fi)
Other versions
FI119738B (sv
FI970115A (sv
Inventor
Jean-Paul Behr
Otmane Boussif
Barbara Demeneix
Franck Lezoualch
Mojgan Mergny
Daniel Scherman
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9465376&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI970115(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of FI970115A0 publication Critical patent/FI970115A0/sv
Publication of FI970115A publication Critical patent/FI970115A/sv
Application granted granted Critical
Publication of FI119738B publication Critical patent/FI119738B/sv

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
FI970115A 1994-07-13 1997-01-10 Komposition som innehåller en lösning av en nukleinsyra och en lösning av en katjonisk polymer och användningar FI119738B (sv)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR9408735A FR2722506B1 (fr) 1994-07-13 1994-07-13 Composition contenant des acides nucleiques, preparation et utilisations
FR9408735 1994-07-13
PCT/FR1995/000914 WO1996002655A1 (fr) 1994-07-13 1995-07-07 Composition contenant des acides nucleiques, preparation et utilisations
FR9500914 1995-07-07

Publications (3)

Publication Number Publication Date
FI970115A0 true FI970115A0 (sv) 1997-01-10
FI970115A FI970115A (sv) 1997-01-10
FI119738B FI119738B (sv) 2009-02-27

Family

ID=9465376

Family Applications (1)

Application Number Title Priority Date Filing Date
FI970115A FI119738B (sv) 1994-07-13 1997-01-10 Komposition som innehåller en lösning av en nukleinsyra och en lösning av en katjonisk polymer och användningar

Country Status (18)

Country Link
US (1) US6013240A (sv)
EP (1) EP0770140B1 (sv)
JP (1) JP4275728B2 (sv)
KR (1) KR100424802B1 (sv)
AT (1) ATE367448T1 (sv)
AU (1) AU2930795A (sv)
CA (1) CA2194797C (sv)
DE (1) DE69535540T9 (sv)
DK (1) DK0770140T3 (sv)
ES (1) ES2290952T3 (sv)
FI (1) FI119738B (sv)
FR (1) FR2722506B1 (sv)
IL (1) IL114566A (sv)
MX (1) MX9700270A (sv)
NO (1) NO323110B1 (sv)
PT (1) PT770140E (sv)
WO (1) WO1996002655A1 (sv)
ZA (1) ZA955849B (sv)

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2730637B1 (fr) 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
US7422902B1 (en) 1995-06-07 2008-09-09 The University Of British Columbia Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
JP4335310B2 (ja) * 1995-06-07 2009-09-30 ザ ユニバーシティ オブ ブリティッシュ コロンビア 疎水性脂質−核酸複合中間体を通して調製される脂質−核酸粒子、及び遺伝子移送のための使用
FR2739292B1 (fr) * 1995-09-28 1997-10-31 Rhone Poulenc Rorer Sa Composition pharmaceutique utile pour la transfection d'acides nucleiques et ses utilisations
GB2324534B (en) * 1996-01-06 2000-05-10 Danbiosyst Uk Composition for delivery of nucleic acid to a cell
JP2001503041A (ja) * 1996-10-23 2001-03-06 エスケーダヴリュ トロストベルグ アクチエンゲゼルシャフト 生物活性ポリマーナノ粒子―核酸接合体の製造方法
JP2001510457A (ja) * 1996-11-12 2001-07-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア インビボ送達に有効な、脂質―核酸複合体の安定な製剤の調製
US6884430B1 (en) * 1997-02-10 2005-04-26 Aventis Pharma S.A. Formulation of stabilized cationic transfection agent(s) /nucleic acid particles
WO1998040510A1 (en) * 1997-03-11 1998-09-17 Regents Of The University Of Minnesota Dna-based transposon system for the introduction of nucleic acid into dna of a cell
US5912225A (en) 1997-04-14 1999-06-15 Johns Hopkins Univ. School Of Medicine Biodegradable poly (phosphoester-co-desaminotyrosyl L-tyrosine ester) compounds, compositions, articles and methods for making and using the same
US6524613B1 (en) 1997-04-30 2003-02-25 Regents Of The University Of Minnesota Hepatocellular chimeraplasty
DE19726186A1 (de) * 1997-06-20 1998-12-24 Boehringer Ingelheim Int Komplexe für den Transport von Nukleinsäure in höhere eukaryotische Zellen
WO1999013915A1 (en) * 1997-09-15 1999-03-25 Genetic Immunity, Llc. Method of delivering genes to antigen presenting cells of the skin
US20020022034A1 (en) * 1997-09-15 2002-02-21 Julianna Lisziewicz Therapeutic DNA vaccination
DE19743135A1 (de) * 1997-09-30 1999-04-01 Hoechst Marion Roussel De Gmbh Biologisch verträgliche niedermolekular Polyethylenimine
CA2335460A1 (en) 1998-06-18 1999-12-23 Johns Hopkins University School Of Medicine Polymers for delivery of nucleic acids
US6916490B1 (en) 1998-07-23 2005-07-12 UAB Research Center Controlled release of bioactive substances
WO2000025748A1 (fr) * 1998-11-02 2000-05-11 Terumo Kabushiki Kaisha Liposomes
US7160682B2 (en) * 1998-11-13 2007-01-09 Regents Of The University Of Minnesota Nucleic acid transfer vector for the introduction of nucleic acid into the DNA of a cell
NZ514415A (en) * 1999-04-02 2005-03-24 Res Dev Foundation Polyethyleneimine:DNA formulations for aerosol delivery
US6770740B1 (en) 1999-07-13 2004-08-03 The Regents Of The University Of Michigan Crosslinked DNA condensate compositions and gene delivery methods
FR2797402B1 (fr) 1999-07-15 2004-03-12 Biomerieux Stelhys Utilisation d'un polypeptide pour detecter, prevenir ou traiter un etat pathologique associe a une maladie degenerative, neurologique ou autoimmune
DE19960206A1 (de) * 1999-12-14 2001-07-19 Frank Czubayko Komplexierung von RNS mit Polyethyleniminen zur deren Stabilisierung und zellulären Einschleusung
EP1156832A1 (en) 1999-12-28 2001-11-28 Transgene S.A. Use of lithium (li?+ ) for the preparation of a composition for transfection of a polynucleotide into a cell and compositions useful in gene therapy
CN1433478A (zh) * 1999-12-30 2003-07-30 诺瓦提斯公司 用于基因治疗的新的胶体合成载体
FR2805271B1 (fr) * 2000-02-18 2002-04-26 Aventis Pharma Sa Procede de preparation de polyalkylenimines fonctionnalises, compositions les contenant et leurs utilisations
FR2813605B1 (fr) * 2000-09-05 2002-10-18 Aventis Pharma Sa Composes acidosensibles, leur preparation et utilisations
US20050085426A1 (en) * 2000-09-05 2005-04-21 Michel Bessodes Acid-sensitive compounds, preparation and use thereof
FR2814370B1 (fr) * 2000-09-22 2004-08-20 Centre Nat Rech Scient Utilisation d'un complexe acide nucleique/pei pour le ciblage de cellules souches du cerveau
DE10145134A1 (de) * 2000-10-09 2002-05-16 Bayer Ag Komplexe zur Einführung von Nukleinsäuren in Zellen
WO2002030468A1 (de) * 2000-10-09 2002-04-18 Bayer Aktiengesellschaft Komplexe zur einführung von nukleinsäuren in zellen
US20020091242A1 (en) * 2000-10-11 2002-07-11 Michel Bessodes Acid-sensitive compounds, their preparation and uses
EP1355628A2 (en) * 2001-02-01 2003-10-29 Board of Regents, The University of Texas System Stabilised polymeric aerosols for pulmonary gene delivery
US6652886B2 (en) 2001-02-16 2003-11-25 Expression Genetics Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents
EP1399189A1 (en) * 2001-06-11 2004-03-24 Universite De Montreal Compositions and methods for enhancing nucleic acid transfer into cells
DK1450856T3 (da) 2001-09-14 2010-05-31 Cytos Biotechnology Ag Pakning af immunstimulatorisk CpG i virus-lignende partilker, fremgangsmåde og anvendelse
AU2002348163A1 (en) * 2001-11-02 2003-05-19 Intradigm Corporation Therapeutic methods for nucleic acid delivery vehicles
DK1466133T3 (da) 2002-01-17 2007-05-14 Johnson Controls Denmark Aps Neddykket fordamper med i sammenbygget forening anordnet (integreret) varmeveksler
AU2003231048A1 (en) * 2002-04-22 2003-11-03 Regents Of The University Of Minnesota Transposon system and methods of use
DE60328383D1 (de) 2002-05-24 2009-08-27 Mirus Bio Corp Zusammensetzungen zur zuführung von nukleinsäuren an zellen
WO2004002453A1 (en) 2002-06-28 2004-01-08 Protiva Biotherapeutics Ltd. Method and apparatus for producing liposomes
EP1537208A1 (en) * 2002-09-13 2005-06-08 Replicor, Inc. Non-sequence complementary antiviral oligonucleotides
US20050196382A1 (en) * 2002-09-13 2005-09-08 Replicor, Inc. Antiviral oligonucleotides targeting viral families
CA2445204C (en) 2002-10-16 2014-08-12 Streck Laboratories, Inc. Method and device for collecting and preserving cells for analysis
US7153905B2 (en) * 2003-03-21 2006-12-26 The General Hospital Corporation Hyperbranched dendron and methods of synthesis and use thereof
AU2004257373B2 (en) 2003-07-16 2011-03-24 Arbutus Biopharma Corporation Lipid encapsulated interfering RNA
NZ592917A (en) 2003-09-15 2012-12-21 Protiva Biotherapeutics Inc Stable polyethyleneglycol (PEG) dialkyloxypropyl (DAA) lipid conjugates
CA2558262A1 (en) * 2004-03-01 2005-09-15 Massachusetts Institute Of Technology Rnai-based therapeutics for allergic rhinitis and asthma
US20050215507A1 (en) * 2004-03-04 2005-09-29 Massachusetts Institute Of Technology Therapeutic anti-cancer DNA
US20060026699A1 (en) * 2004-06-04 2006-02-02 Largaespada David A Methods and compositions for identification of genomic sequences
EP1781593B1 (en) 2004-06-07 2011-12-14 Protiva Biotherapeutics Inc. Cationic lipids and methods of use
ATE536418T1 (de) 2004-06-07 2011-12-15 Protiva Biotherapeutics Inc Lipidverkapselte interferenz-rna
JP2008504827A (ja) 2004-07-02 2008-02-21 プロチバ バイオセラピューティクス インコーポレイティッド 免疫賦活性siRNA分子およびその使用方法
EP1948674A4 (en) 2005-11-02 2009-02-04 Protiva Biotherapeutics Inc MODIFIED SIRNA MOLECULES AND APPLICATIONS THEREOF
US7915399B2 (en) 2006-06-09 2011-03-29 Protiva Biotherapeutics, Inc. Modified siRNA molecules and uses thereof
US20080312174A1 (en) * 2007-06-05 2008-12-18 Nitto Denko Corporation Water soluble crosslinked polymers
WO2009036368A2 (en) * 2007-09-14 2009-03-19 Nitto Denko Corporation Drug carriers
EP2047858A1 (en) 2007-10-10 2009-04-15 Institut National De La Sante Et De La Recherche Medicale (Inserm) Combination products for treating cancer
DE102008016275A1 (de) 2008-03-28 2009-11-19 Biontex Laboratories Gmbh Verbesserung von Transfektionsergebnissen nicht-viraler Genliefersysteme durch Blockierung des angeborenen Immunsystems
DE102008023913A1 (de) 2008-05-16 2009-11-19 Biontex Laboratories Gmbh Verbesserung von Transfektionsergebnissen nicht-viraler Genliefersysteme durch Beeinflussung des angeborenen Immunsystems
DE102007056488A1 (de) 2007-11-22 2009-07-23 Biontex Laboratories Gmbh Steigerung von Transfektionseffizienzen nicht-viraler Genliefersysteme durch Blockierung des angeborenen Immunsystems
EP2363494A1 (de) 2007-11-22 2011-09-07 Biontex Laboratories Gmbh Verbesserung von Transfektionsergebnissen nicht-viraler Genliefersysteme durch Beeinflussung des angeborenen Immunsystems
GB0724253D0 (en) 2007-12-12 2008-01-30 Fermentas Uab Transfection reagent
WO2009082817A1 (en) 2007-12-27 2009-07-09 Protiva Biotherapeutics, Inc. Silencing of polo-like kinase expression using interfering rna
US7687027B2 (en) * 2008-02-27 2010-03-30 Becton, Dickinson And Company Cleaning compositions, methods and materials for reducing nucleic acid contamination
FR2928373B1 (fr) 2008-03-05 2010-12-31 Centre Nat Rech Scient Polymere derive de la polyethylenimine lineaire pour le transfert de gene.
AU2009238175C1 (en) 2008-04-15 2023-11-30 Arbutus Biopharma Corporation Novel lipid formulations for nucleic acid delivery
EP2770057A1 (en) 2008-04-15 2014-08-27 Protiva Biotherapeutics Inc. Silencing of CSN5 gene expression using interfering RNA
DK2285969T3 (da) * 2008-05-15 2013-04-08 Ca Nat Research Council Anvendelse af proteinkinase b og valproinsyre for at forøge heterolog genekspression i pattedyrsceller
AU2009303345B2 (en) 2008-10-09 2015-08-20 Arbutus Biopharma Corporation Improved amino lipids and methods for the delivery of nucleic acids
WO2010078194A1 (en) * 2008-12-30 2010-07-08 Streck, Inc. Method for screening blood using a preservative that may be in a substantially solid state form
US11634747B2 (en) * 2009-01-21 2023-04-25 Streck Llc Preservation of fetal nucleic acids in maternal plasma
DE102009006606A1 (de) 2009-01-29 2010-08-05 Philipps-Universität Marburg Nicht-virales Transfektionsmittel
EP3290530B1 (en) 2009-02-18 2020-09-02 Streck Inc. Preservation of cell-free nucleic acids
EP2623117A1 (en) 2009-04-30 2013-08-07 Genetic Immunity Kft. Immunogenic nanomedicine composition and preparation and uses thereof
US9018187B2 (en) 2009-07-01 2015-04-28 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
CA2767127A1 (en) 2009-07-01 2011-01-06 Protiva Biotherapeutics, Inc. Novel lipid formulations for delivery of therapeutic agents to solid tumors
WO2011000106A1 (en) 2009-07-01 2011-01-06 Protiva Biotherapeutics, Inc. Improved cationic lipids and methods for the delivery of therapeutic agents
US9856456B2 (en) * 2009-10-12 2018-01-02 Thermo Fisher Scientific Baltics Uab Delivery agent
CA2780741C (en) 2009-10-12 2023-04-04 Smith Holdings, Llc Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
GB0917792D0 (en) 2009-10-12 2009-11-25 Fermentas Uab Delivery agent
ES2571104T3 (es) * 2009-11-09 2016-05-24 Streck Inc Estabilización del ARN y extracción del ARN presente en células intactas dentro de una muestra de sangre
EP2549859B1 (en) 2010-03-24 2017-06-21 Institut National de la Santé et de la Recherche Medicale Primate model from the family Cercopithecidae infected by a HBV strain of human genotype
US8945927B2 (en) 2010-03-29 2015-02-03 Universite De Strasbourg Polymers for delivering molecules of interest
JP2013530187A (ja) 2010-06-17 2013-07-25 ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティッド バイ ザ シークレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ 炎症性疾患を治療するための組成物及び方法。
PT3135301T (pt) 2010-06-22 2018-07-16 Inst Curie Sistema de administração otimizado in vivo com agentes endossomolíticos para conjugados de ácidos nucleicos
WO2012000104A1 (en) 2010-06-30 2012-01-05 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
WO2012151391A2 (en) 2011-05-04 2012-11-08 Streck, Inc. Inactivated virus compositions and methods of preparing such compositions
WO2013040552A2 (en) 2011-09-16 2013-03-21 Georgia Health Sciences University Methods of promoting immune tolerance
JP2014533953A (ja) 2011-11-17 2014-12-18 ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ 治療用rnaスイッチ組成物及び使用方法
CN109097398A (zh) 2011-11-24 2018-12-28 吉尼松公司 与工业制药应用相容的可放大的慢病毒载体生产系统
US9035039B2 (en) 2011-12-22 2015-05-19 Protiva Biotherapeutics, Inc. Compositions and methods for silencing SMAD4
CA2873274C (en) * 2012-06-08 2021-06-01 Ethris Gmbh Pulmonary delivery of messenger rna
CN103059295B (zh) * 2012-09-26 2016-01-13 上海交通大学 疏水修饰的聚乙烯亚胺及其作为蛋白质载体的用途
HUE059435T2 (hu) 2012-10-05 2022-11-28 Biontech Delivery Tech Gmbh Hidroxilált poliamin-származékok mint transzfekciós reagensek
US9677078B2 (en) 2012-10-08 2017-06-13 Lipocalyx Gmbh Carboxylated polyamine derivatives as transfection reagents
DE102012111891A1 (de) * 2012-12-06 2014-06-12 Eberhard Karls Universität Tübingen Medizinische Fakultät Verbesserung der Zielfindungskapazität von Stammzellen
WO2015013244A1 (en) 2013-07-24 2015-01-29 Streck, Inc. Compositions and methods for stabilizing circulating tumor cells
EP3068891A1 (en) 2013-11-13 2016-09-21 Aequus Biopharma Inc. Engineered glycoproteins and uses thereof
JP2017536092A (ja) 2014-10-02 2017-12-07 プロティバ バイオセラピューティクス インコーポレイテッド B型肝炎ウイルスの遺伝子発現をサイレンシングするための組成物及び方法
EP3034539A1 (en) * 2014-12-19 2016-06-22 Ethris GmbH Compositions for introducing nucleic acid into cells
US11168351B2 (en) 2015-03-05 2021-11-09 Streck, Inc. Stabilization of nucleic acids in urine
CN107735079A (zh) 2015-05-05 2018-02-23 耶路撒冷希伯来大学伊森姆研究发展有限公司 核酸‑阳离子聚合物组合物及其制备和使用方法
US20180245074A1 (en) 2015-06-04 2018-08-30 Protiva Biotherapeutics, Inc. Treating hepatitis b virus infection using crispr
WO2017019891A2 (en) 2015-07-29 2017-02-02 Protiva Biotherapeutics, Inc. Compositions and methods for silencing hepatitis b virus gene expression
US20170145475A1 (en) 2015-11-20 2017-05-25 Streck, Inc. Single spin process for blood plasma separation and plasma composition including preservative
US10010627B2 (en) 2016-06-03 2018-07-03 International Business Machines Corporation Modified polycationic polymers
WO2018022991A1 (en) 2016-07-29 2018-02-01 Streck, Inc. Suspension composition for hematology analysis control
CA3044074A1 (en) 2016-11-16 2018-05-24 Immunomic Therapeutics, Inc. Nucleic acids for treatment of allergies
WO2018134310A1 (en) 2017-01-19 2018-07-26 Universiteit Gent Molecular adjuvants for enhanced cytosolic delivery of active agents
CA3061206A1 (en) 2017-04-22 2018-10-25 Immunomic Therapeutics, Inc. Improved lamp constructs
IL270271B2 (en) 2017-05-02 2023-03-01 Immunomic Therapeutics Inc LAMP structures containing cancer antigens
EP3793595A1 (en) 2018-05-15 2021-03-24 Immunomic Therapeutics, Inc. Improved lamp constructs comprising allergens
TW202043256A (zh) 2019-01-10 2020-12-01 美商健生生物科技公司 前列腺新抗原及其用途
WO2021077051A1 (en) 2019-10-18 2021-04-22 Immunomic Therapeutics, Inc Improved lamp constructs comprising cancer antigens
IL293051A (en) 2019-11-18 2022-07-01 Janssen Biotech Inc calr and jak2 mutant-based vaccines and their uses
WO2022009052A2 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
US20230024133A1 (en) 2020-07-06 2023-01-26 Janssen Biotech, Inc. Prostate Neoantigens And Their Uses
WO2022009051A1 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. A method for determining responsiveness to prostate cancer treatment
CN112237633B (zh) * 2020-10-22 2023-06-27 林君玉 一种pei/on复合物及其制备方法和用途
JP2023553343A (ja) 2020-11-25 2023-12-21 アカゲラ・メディスンズ,インコーポレイテッド 核酸を送達するための脂質ナノ粒子および関連する使用方法
WO2022258967A1 (en) 2021-06-08 2022-12-15 Touchlight IP Limited Lentiviral vector
GB202108176D0 (en) 2021-06-08 2021-07-21 Touchlight Ip Ltd Vector
WO2023201201A1 (en) 2022-04-10 2023-10-19 Immunomic Therapeutics, Inc. Bicistronic lamp constructs comprising immune response enhancing genes and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5286634A (en) * 1989-09-28 1994-02-15 Stadler Joan K Synergistic method for host cell transformation
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5283185A (en) * 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
AU3945493A (en) * 1992-04-06 1993-11-08 University Of Medicine And Dentistry Of New Jersey Paired-ion oligonucleotides and methods for preparing same
US6172208B1 (en) * 1992-07-06 2001-01-09 Genzyme Corporation Oligonucleotides modified with conjugate groups
US5334761A (en) * 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids

Also Published As

Publication number Publication date
MX9700270A (es) 1997-05-31
JPH10502918A (ja) 1998-03-17
FR2722506A1 (fr) 1996-01-19
AU2930795A (en) 1996-02-16
US6013240A (en) 2000-01-11
NO970049D0 (no) 1997-01-07
DE69535540D1 (de) 2007-08-30
ATE367448T1 (de) 2007-08-15
DE69535540T2 (de) 2008-06-19
CA2194797A1 (fr) 1996-02-01
NO323110B1 (no) 2007-01-02
JP4275728B2 (ja) 2009-06-10
EP0770140A1 (fr) 1997-05-02
KR970704889A (ko) 1997-09-06
ZA955849B (en) 1996-02-21
IL114566A0 (en) 1995-11-27
ES2290952T3 (es) 2008-02-16
NO970049L (no) 1997-01-07
KR100424802B1 (ko) 2004-06-23
DK0770140T3 (da) 2007-11-19
EP0770140B1 (fr) 2007-07-18
FI119738B (sv) 2009-02-27
FR2722506B1 (fr) 1996-08-14
FI970115A (sv) 1997-01-10
WO1996002655A1 (fr) 1996-02-01
IL114566A (en) 2005-08-31
PT770140E (pt) 2007-10-19
CA2194797C (fr) 2010-03-23
DE69535540T9 (de) 2012-03-15

Similar Documents

Publication Publication Date Title
FI970115A0 (sv) Komposition innehållande nukleinsyror, dess framställning och användningar
FI962799A0 (sv) Komposition innehållande nukleinsyror, dess framställning och användning
FR2715847B1 (fr) Composition contenant des acides nucléiques, préparation et utilisations.
DE69829287D1 (de) Verbesserung der verabreichung der nukleinsäure in zellen der plurizellulären eukaryotischen organismen und kombination zur durchführung des verfahrens
FI973467A (sv) DNA-molekyler, framställning och användning i genterapi
NZ289720A (en) Nucleic acids coding for a telomerase, a ribonucleoprotein enzyme involved in telomere synthesis
BR9810369A (pt) Processo de transferência de ácido nucleico para o interior de um ou mais músculos estriados, in vivo, composição, ácido mucleico e campo elétrico, e, produto de combinação
EP0957926A4 (en) OLIGONUCLEOTIDE COMPOSITION AND METHOD FOR REGULATING THE PROTEIN B7 EXPRESSION
ATE224736T1 (de) Kombinationsprodukt, enthaltend eine nukleinsäure und eine substanz, die die extrazellulärematrix desorganisiert, zur verwendung in gentherapie
EP1123414A4 (en) ANTISENSE MODULATION OF THE EXPRESSION OF INTEGRIN ALPHA 4
DE69228997T2 (de) Menschliche il-3-varianten
HUT77029A (hu) A GAP-protein SH3 doménjéhez kötődni képes peptidek, ezeket kódoló nukleotidszekvenciák és előállításuk és alkalmazásuk
BR9910787A (pt) Métodos e composições úteis para modulação deangiogênese usando tirosina cinase src
HK1002658A1 (en) Imidazopyridine-azolidinones their preparation and pharmaceutical use
NO983103L (no) Nye monofunksjonelle EDTA-, DTPA- og TTHA-derivater og deres anvendelse i medisinsk diagnostikk og terapi
ZA966577B (en) Pharmaceutical composition.
ATE221895T1 (de) Chimäre oligonucleotide und ihre verwendung
BR9712210A (pt) Processos de preparação de uma composição para a transferência de ácidos nucléicos e para a transferência de ácido nucléico em células in vitro ou ex vivo, e, composição para a transferência de ácidos nucléicos.

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 119738

Country of ref document: FI

MA Patent expired